Skip to main content
. Author manuscript; available in PMC: 2026 Jul 23.
Published in final edited form as: Stem Cell Res. 2026 Apr 1;94:103977. doi: 10.1016/j.scr.2026.103977
Unique stem cell line identifier 1) SCVIi134-A
2) SCVIi137-A

Alternative name(s) of stem cell lines 1) SCVI 692 (SCVIi134-A)
2) SCVI 770 (SCVIi137-A)
Institution Stanford Cardiovascular Institute
Contact information of the distributor Joseph C. Wu
Type of cell lines iPSCs
Origin Human
Additional origin info is required for human ESC or iPSC Age: 60 (SCVIi134-A), 64 (SCVIi137-A), Sex: Female (both lines), Ethnicity if known: White (both lines)
Cell Source PBMC
Clonality Clonal
Method of reprogramming Sendai virus vectors
Genetic Modification Yes
Type of Genetic Modification Spontaneous mutation
Evidence of the reprogramming transgene loss (including genomic copy if applicable) RT-qPCR
Associated disease Myotonic Dystrophy Type 1 (DM1, OMIM ID: 160900)
Gene/locus DMPK, 19q13.32, CTG repeat expansion
Date archived/stock date 1) 11/18/2022 (SCVIi134-A)
2) 01/06/2021 (SCVIi137-A)
Cell line repository/bank SCVi134-A: https://hpscreg.eu/cell-line/SCVIi134-A
SCVi137-A: https://hpscreg.eu/cell-line/SCVIi137-A
Ethical approval The Administrative Panel on Human Subjects Research (IRB) granted approval for the lines’ production under IRB #29904, “Derivation of Human-Induced Pluripotent Stem Cells (Biorepository).